Barely Significant
← all excerpts

Pharmacovigilance analysis of cutaneous adverse drug reactions for cetuximab, panitumumab, and necitumumab based on EudraVigilance and WHO VigiAccess.

Front Pharmacol · 2026 · PMC13291479 · PMID 42358356

Europe PMCDOI
1
hedged sentence
0.0001
closest p · 0.0× alpha
0.0001
boldest claim

The sentences

highly significantp < 0.0001actually significant
The test revealed a highly significant association (χ 2 (38) = 3616.46, p < 0.0001, V = .12), indicating that the SOC profile of ADRs varies substantially depending on the anti-EGFR agent.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.